Electra Therapeutics (NASDAQ:ETRA) Stock: Insider Carl Gordon Purchases 22,700 Shares

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon purchased 22,700 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $8.45 per share, with a total value of $191,815.00. Following the completion of the acquisition, the director owned 5,255,278 shares of the company’s stock, valued at approximately $44,407,099.10. The trade was a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Electra Therapeutics Trading Up 18.3%

Shares of NASDAQ:ETRA opened at $9.45 on Thursday. Electra Therapeutics, Inc. has a 52-week low of $6.86 and a 52-week high of $15.50.

Top Electra Therapeutics Stories

Investors following ETRA have been watching these stories:

• Positive Sentiment: OrbiMed reported buying 92,116 shares on November 6, 9 and 10 for about $744,500 in total, adding to purchases earlier in November. Repeated insider buying may support investor confidence, though it does not guarantee future performance. Insider purchase report
• Neutral Sentiment: A short-interest update reported zero shares short and zero days to cover as of November 10, but also described short interest as having increased, an apparent inconsistency that makes the data difficult to interpret.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright began coverage on shares of Electra Therapeutics in a research note on Monday, October 26th. They issued a “buy” rating and a $30.00 target price for the company. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. Jefferies Financial Group initiated coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target for the company. Evercore started coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Electra Therapeutics currently has an average rating of “Buy” and a consensus target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.